Adam S Garden

List of Publications by Citations

368 papers	21,261 citations	76 h-index	134 g-index
381 ext. papers	24,564 ext. citations	3.3 avg, IF	6.23 L-index

#	Paper	IF	Citations
368	A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. *International Journal of Radiation Oncology Biology Physics*, **2000**, 48, 7-16	4	1075
367	Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. *Journal of Clinical Oncology*, **2008**, 26, 3582-9	2.2	977
366	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *Journal of Clinical Oncology*, **2014**, 32, 2940-50	2.2	547
365	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 960-70	4	515
364	Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. *Journal of Clinical Oncology*, **2009**, 27, 3684-90	2.2	491
363	Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 571-8	4	474
362	Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. *Physics in Medicine and Biology*, **2005**, 50, 2887-905	3.8	459
361	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. *Lancet Oncology, The*, **2016**, 17, 440-451	21.7	448
360	Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. *International Journal of Radiation Oncology Biology Physics*, **1993**, 26, 3-11	4	409
359	Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. *Journal of Clinical Oncology*, **2014**, 32, 3365-73	2.2	352
358	The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. *International Journal of Radiation Oncology Biology Physics*, **1995**, 32, 619-26	4	338
357	Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 1110-20	4	323
356	Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. *Cancer*, **2008**, 113, 2704-13	6.4	258
355	Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 1333-8	4	256
354	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. *Lancet Oncology, The*, **2012**, 13, 172-80	21.7	234
353	Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. *International Journal of Radiation Oncology Biology Physics*, **1997**, 37, 985-96	4	225
352	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *Journal of Clinical Oncology*, **2010**, 28, 8-14	2.2	191

351	Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. *Head and Neck*, **2004**, 26, 796-807	4.2	179
350	IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 399-409	4	178
349	Parathyroid carcinoma: a 22-year experience. *Head and Neck*, **2004**, 26, 716-26	4.2	178
348	Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. *International Journal of Radiation Oncology Biology Physics* , **1995**, 33, 179-82	4	173
347	Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. *Cancer*, **1995**, 76, 319-27	6.4	170
346	Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. *Head and Neck*, **2007**, 29, 923-31	4.2	168
345	Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. *Cancer*, **2004**, 101, 2567-73	6.4	164
344	Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. *Journal of Clinical Oncology*, **2008**, 26, 5119-25	2.2	163
343	TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. *Lancet Oncology, The*, **2007**, 8, 613-24	21.7	159
342	Postoperative radiotherapy for cutaneous melanoma of the head and neck region. *International Journal of Radiation Oncology Biology Physics*, **1994**, 30, 795-8	4	159
341	Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 986-93	4	152
340	Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. *Cancer*, **1994**, 73, 2563-9	6.4	152
339	Postoperative radiotherapy for malignant tumors of the parotid gland. *International Journal of Radiation Oncology Biology Physics*, **1997**, 37, 79-85	4	150
338	Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 415-20	4	146
337	Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. *Journal of Clinical Oncology*, **2004**, 22, 2856-64	2.2	146
336	Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. *Radiotherapy and Oncology*, **1997**, 43, 53-61	5.3	144
335	Adult rhabdomyosarcoma: outcome following multimodality treatment. *Cancer*, **2002**, 95, 377-88	6.4	144
334	Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 747-55	4	143

333	Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 13-20	4	142
332	Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. *Journal of Clinical Oncology* , **2009**, 27, 2509-15	2.2	142
331	Multiple regions-of-interest analysis of setup uncertainties for head-and-neck cancer radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 1559-69	4	141
330	Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. *Journal of Clinical Oncology*, **2005**, 23, 3008-15	2.2	141
329	Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 1356-65	4	130
328	Prognostic factors in mucoepidermoid carcinoma of the salivary glands. *Cancer*, **2012**, 118, 3928-36	6.4	129
327	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiotherapy and Oncology*, **2016**, 120, 48-55	5.3	129
326	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. *JAMA Oncology*, **2016**, 2, 782-9	13.4	126
325	Adaptive radiotherapy for head and neck cancer--dosimetric results from a prospective clinical trial. *Radiotherapy and Oncology*, **2013**, 106, 80-4	5.3	123
324	Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 438-44	4	117
323	Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 322-8	4	115
322	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. *Cancer*, **2013**, 119, 81-9	6.4	114
321	Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. *Radiotherapy and Oncology*, **1991**, 20, 99-110	5.3	113
320	Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get?. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1290-6	4	112
319	Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. *International Journal of Radiation Oncology Biology Physics*, **2009**, 74, 1083-91	4	108
318	Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. *Head and Neck*, **1996**, 18, 552-9	4.2	108
317	A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 674-81	4	107
316	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 618-627	4	107

315	Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. *Cancer*, **2014**, 120, 702-10	6.4	106
314	Minor salivary gland tumors of the palate: clinical and pathologic correlates of outcome. *Laryngoscope*, **1995**, 105, 1155-60	3.6	104
313	Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. *Journal of Clinical Oncology*, **2001**, 19, 3010-7	2.2	101
312	Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 916-25	4	100
311	Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. *International Journal of Radiation Oncology Biology Physics*, **2014**, 89, 846-53	4	99
310	Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. *Head and Neck*, **1998**, 20, 674-81	4.2	98
309	Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. *Cancer*, **2012**, 118, 2872-8	6.4	96
308	Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. *Journal of Pain and Symptom Management*, **2009**, 38, 522-32	4.8	93
307	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. *Cancer*, **2015**, 121, 294-301	6.4	90
306	Adjuvant irradiation for cervical lymph node metastases from melanoma. *Cancer*, **2003**, 97, 1789-96	6.4	89
305	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1107-14	4	88
304	Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 941-7	4	88
303	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. *Cancer*, **2014**, 120, 1975-84	6.4	87
302	Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 1351-5	4	85
301	Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 210-9	4	85
300	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 30-41	4	82
299	Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. *Head and Neck*, **2013**, 35, 1707-12	4.2	81
298	Unilateral radiotherapy for the treatment of tonsil cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 204-9	4	80

297	Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. *Cancer*, **2015**, 121, 1608-19	6.4	78
296	Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. *International Journal of Radiation Oncology Biology Physics*, **1990**, 19, 31-6	4	77
295	Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. *Cancer*, **2007**, 109, 1914-22	6.4	76
294	Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. *Journal of Clinical Oncology*, **2006**, 24, 2092-7	2.2	76
293	Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. *Radiation Oncology*, **2013**, 8, 21	4.2	75
292	Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?. *Cancer*, **2004**, 100, 1171-8	6.4	75
291	Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. *Head and Neck*, **2016**, 38 Suppl 1, E1886-95	4.2	74
290	DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. *Clinical Cancer Research*, **2011**, 17, 2035-43	12.9	74
289	Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. *Medical Dosimetry*, **2013**, 38, 390-4	1.3	72
288	Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 455-61	4	72
287	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: comparison of split-field and whole-field techniques. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 1000-5	4	72
286	Complications of radiotherapy in laryngopharyngeal cancer: effects of a prospective smoking cessation program. *Cancer*, **2009**, 115, 4636-44	6.4	71
285	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. *Thyroid*, **2018**, 28, 945-951	6.2	71
284	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1117-31	4	70
283	Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. *International Journal of Radiation Oncology Biology Physics*, **2007**, 68, 719-30	4	70
282	Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 678-83	4	68
281	Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. *Head and Neck*, **2010**, 32, 829-36	4.2	67
280	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. *Radiotherapy and Oncology*, **2014**, 112, 321-5	5.3	65

279	Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **1995**, 33, 289-96	4	65
278	Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. *Head and Neck*, **2008**, 30, 883-8	4.2	63
277	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. *Radiotherapy and Oncology*, **2016**, 118, 304-14	5.3	63
276	Management of nonsinonasal neuroendocrine carcinomas of the head and neck. *Cancer*, **2003**, 98, 2322-8	6.4	62
275	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 360-367	4	61
274	Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 1005-10	4	61
273	Importance of patient examination to clinical quality assurance in head and neck radiation oncology. *Head and Neck*, **2006**, 28, 967-73	4.2	60
272	Postoperative radiotherapy for malignant tumors of the submandibular gland. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 952-8	4	60
271	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. *Radiotherapy and Oncology*, **2016**, 121, 381-386	5.3	60
270	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. *Journal of Clinical Oncology*, **2016**, 34, 1848-54	2.2	59
269	Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 1002-1011	4	59
268	Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 75, 725-33	4	59
267	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. *Cancer*, **2004**, 100, 383-9	6.4	59
266	The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 1355-61	4	57
265	Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 353-60	4	55
264	Ethmoid sinus carcinomas: natural history and treatment results. *Radiotherapy and Oncology*, **1998**, 49, 21-7	5.3	55
263	Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience. *Head and Neck*, **1994**, 16, 39-44	4.2	55
262	Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. *Journal of Clinical Oncology*, **2006**, 24, 4163-9	2.2	54

261	Radiation therapy for early-stage carcinoma of the oropharynx. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 743-51	4	54
260	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. *International Journal of Particle Therapy*, **2015**, 2, 19-28	1.5	54
259	Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. *Oral Oncology*, **2019**, 88, 66-74	4.4	53
258	Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 721-9	4	52
257	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. *Seminars in Radiation Oncology*, **2004**, 14, 103-9	5.5	52
256	Electron conformal radiotherapy using bolus and intensity modulation. *International Journal of Radiation Oncology Biology Physics*, **2002**, 53, 1023-37	4	52
255	Radiation Therapy for Nonmelanoma Skin Carcinomas. *Clinics in Plastic Surgery*, **1997**, 24, 719-729	3	51
254	Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. *Journal of Clinical Oncology*, **2006**, 24, 4177-83	2.2	51
253	Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. *JAMA Otolaryngology*, **2005**, 131, 874-8		51
252	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. *Medical Dosimetry*, **2016**, 41, 189-94	1.3	50
251	Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, e367-74	4	50
250	Primary carcinoma of the female urethra. Results of radiation therapy. *Cancer*, **1993**, 71, 3102-8	6.4	50
249	Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, 983-9	4	49
248	Outcomes of malignant tumors of the lacrimal apparatus: the University of Texas MD Anderson Cancer Center experience. *Cancer*, **2011**, 117, 2801-10	6.4	49
247	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. *Cancer*, **2002**, 95, 322-30	6.4	48
246	Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. *Cancer*, **2008**, 112, 111-8	6.4	47
245	Long-term radiotherapy outcomes for nasal cavity and septal cancers. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 401-6	4	47
244	Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. *Journal of Clinical Oncology*, **1999**, 17, 2390-5	2.2	47

243	Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. *International Journal of Radiation Oncology Biology Physics*, **1995**, 31, 493-502	4	47
242	Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. *Head and Neck*, **1996**, 18, 317-22	4.2	47
241	Can positron emission tomography improve the quality of care for head-and-neck cancer patients?. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 4-9	4	46
240	Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. *Cancer*, **1997**, 79, 1279-86	6.4	45
239	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. *Cancer*, **2016**, 122, 534-45	6.4	45
238	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. *Cancer*, **2017**, 123, 1653-1661	6.4	44
237	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. *Radiotherapy and Oncology*, **2017**, 123, 401-405	5.3	43
236	Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. *Journal of Oral and Maxillofacial Surgery*, **2004**, 62, 139-44	1.8	43
235	Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. *Cancer*, **2003**, 98, 2214-23	6.4	43
234	Quality assurance assessment of diagnostic and radiation therapy-simulation CT image registration for head and neck radiation therapy: anatomic region of interest-based comparison of rigid and deformable algorithms. *Radiology*, **2015**, 274, 752-63	20.5	42
233	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: a SEER-Medicare analysis. *Head and Neck*, **2013**, 35, 1599-605	4.2	42
232	New thoughts on the pathobiology of regimen-related mucosal injury. *Supportive Care in Cancer*, **2006**, 14, 516-8	3.9	41
231	Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). *Cancer*, **2012**, 118, 5783-92	6.4	40
230	The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. *Cancer*, **2007**, 109, 2052-7	6.4	40
229	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 665-71	4	40
228	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 532-540	4	39
227	Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. *Head and Neck*, **2014**, 36, 474-80	4.2	39
226	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. *Cancer*, **2013**, 119, 3162-9	6.4	39

225	Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. *Ophthalmic Plastic and Reconstructive Surgery*, **2008**, 24, 444-9	1.4	39
224	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. *Radiotherapy and Oncology*, **2017**, 124, 232-239	5.3	38
223	Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. *Radiotherapy and Oncology*, **2014**, 111, 281-8	5.3	38
222	Controversies in surgical management of the node-positive neck after chemoradiation. *Seminars in Radiation Oncology*, **2009**, 19, 24-8	5.5	37
221	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 344-352	4	37
220	Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1369-76	4	36
219	Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. *Cancer*, **2008**, 112, 2698-709	6.4	36
218	Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. *Cancer*, **2011**, 117, 1679-86	6.4	35
217	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. *Journal of Clinical Oncology*, **2009**, 27, 1976-82	2.2	35
216	Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. *International Journal of Radiation Oncology Biology Physics*, **1997**, 39, 127-35	4	35
215	Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?. *Head and Neck*, **2005**, 27, 718-21	4.2	35
214	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. *NMR in Biomedicine*, **2015**, 28, 1645-54	4.4	34
213	Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **1996**, 35, 455-62	4	34
212	Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 700-708	4	33
211	Automatic detection of contouring errors using convolutional neural networks. *Medical Physics*, **2019**, 46, 5086-5097	4.4	33
210	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. *Cancer*, **2004**, 100, 991-8	6.4	33
209	A multimodality segmentation framework for automatic target delineation in head and neck radiotherapy. *Medical Physics*, **2015**, 42, 5310-20	4.4	32
208	Prognostic factors associated with decreased survival in patients with acinic cell carcinoma. *JAMA Otolaryngology - Head and Neck Surgery*, **2013**, 139, 1195-202	3.9	32

207	Radiation therapy for early stage (T1-T2) sarcomatoid carcinoma of true vocal cords: outcomes and patterns of failure. *Laryngoscope*, **1998**, 108, 760-3	3.6	32
206	Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. *Journal of Clinical Oncology*, **2009**, 27, 4727-32	2.2	31
205	Intensity-modulated radiotherapy: is xerostomia still prevalent?. *Current Oncology Reports*, **2005**, 7, 131-**6**.3		31
204	Carcinomas of the nasal cavity. *Radiotherapy and Oncology*, **1992**, 24, 163-8	5.3	31
203	Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes. *Radiation Oncology*, **2014**, 9, 255	4.2	30
202	Identifying early dehydration risk with home-based sensors during radiation treatment: a feasibility study on patients with head and neck cancer. *Journal of the National Cancer Institute Monographs*, **2013**, 2013, 162-8	4.8	30
201	Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. *International Journal of Radiation Oncology Biology Physics*, **1996**, 36, 1005-12	4	30
200	A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. *Practical Radiation Oncology*, **2015**, 5, e169-e176	2.8	29
199	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 687-699	4	29
198	Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center. *Skull Base*, **1996**, 6, 1-8		28
197	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. *Practical Radiation Oncology*, **2016**, 6, 241-247	2.8	28
196	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 724-733	4	28
195	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. *Clinical Cancer Research*, **2020**, 26, 3211-3219	12.9	28
194	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. *Head and Neck*, **2016**, 38, 1739-1751	4.2	26
193	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. *Laryngoscope*, **2017** , 127, 842-848	3.6	25
192	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. *JAMA Otolaryngology - Head and Neck Surgery*, **2019**, 145, 1053-1063	3.9	25
191	Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. *Head and Neck*, **2009**, 31, 1031-8	4.2	25
190	The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 191-8	2.7	25

189	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. *Head and Neck*, **2016**, 38 Suppl 1, E1472-80	4.2	24
188	Impact of gender, partner status, and race on locoregional failure and overall survival in head and neck cancer patients in three radiation therapy oncology group trials. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e101-9	4	24
187	Auto-delineation of oropharyngeal clinical target volumes using 3D convolutional neural networks. *Physics in Medicine and Biology*, **2018**, 63, 215026	3.8	24
186	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1346-1354	4	23
185	Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. *Cancer*, **2014**, 120, 3082-8	6.4	23
184	Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer. *Radiation Oncology*, **2012**, 7, 19	4.2	23
183	Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. *Physics in Medicine and Biology*, **2017**, 62, 9140-9158	3.8	23
182	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. *International Journal of Clinical Oncology*, **2007**, 12, 99-110	4.2	23
181	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. *Head and Neck*, **2016**, 38 Suppl 1, E452-8	4.2	23
180	Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. *Journal of Applied Clinical Medical Physics*, **2016**, 17, 180-189	2.3	23
179	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. *Scientific Data*, **2018**, 5, 180173	8.2	22
178	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. *Radiation Oncology*, **2016**, 11, 95	4.2	22
177	Depression and Oropharynx Cancer Outcome. *Psychosomatic Medicine*, **2016**, 78, 38-48	3.7	22
176	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. *Head and Neck*, **2016**, 38 Suppl 1, E1459-66	4.2	21
175	Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. *Head and Neck*, **2017**, 39, 1516-1523	4.2	20
174	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. *Seminars in Radiation Oncology*, **2018**, 28, 108-113	5.5	20
173	Radiation-associated head and neck sarcomas: spectrum of imaging findings. *Oral Oncology*, **2012**, 48, 155-61	4.4	20
172	Auto-segmentation of low-risk clinical target volume for head and neck radiation therapy. *Practical Radiation Oncology*, **2014**, 4, e31-7	2.8	20

171	Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 667-74	4	20
170	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 717-24	4	20
169	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. *Clinical and Translational Radiation Oncology*, **2018**, 13, 19-23	4.6	20
168	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. *Radiotherapy and Oncology*, **2015**, 117, 132-8	5.3	19
167	Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis. *Cancer*, **2017**, 123, 283-293	6.4	19
166	Mucositis: current management and investigations. *Seminars in Radiation Oncology*, **2003**, 13, 267-73	5.5	19
165	Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. *Head and Neck*, **2016**, 38 Suppl 1, E925-33	4.2	19
164	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. *Radiation Oncology*, **2017**, 12, 150	4.2	18
163	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. *Radiotherapy and Oncology*, **2002**, 63, 187-93	5.3	18
162	Water bolus for electron irradiation of the ear canal. *International Journal of Radiation Oncology Biology Physics*, **1995**, 33, 479-83	4	18
161	Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. *Oral Oncology*, **2017**, 72, 90-97	4.4	18
160	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. *3D Printing in Medicine*, **2017**, 3, 12	5	17
159	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. *Clinical and Translational Radiation Oncology*, **2019**, 18, 16-22	4.6	17
158	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. *Practical Radiation Oncology*, **2014**, 4, e189-94	2.8	17
157	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. *Radiotherapy and Oncology*, **2017**, 124, 248-255	5.3	17
156	How to reduce radiation-related toxicity in patients with cancer of the head and neck. *Current Oncology Reports*, **2006**, 8, 140-5	6.3	17
155	Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck. *Cancer*, **1995**, 75, 2356-60	6.4	17
154	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. *Oral Oncology*, **2016**, 61, 62-9	4.4	17

153	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. *Npj Precision Oncology*, **2019**, 3, 22	9.8	16
152	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. *Head and Neck*, **2020**, 42, 1939-1953	4.2	16
151	Nomogram for predicting symptom severity during radiation therapy for head and neck cancer. *Otolaryngology - Head and Neck Surgery*, **2014**, 151, 619-26	5.5	16
150	Variable planning margin approach to account for locoregional variations in setup uncertainties. *Medical Physics*, **2012**, 39, 5136-44	4.4	16
149	Development and validation of a 3D-printed bolus cap for total scalp irradiation. *Journal of Applied Clinical Medical Physics*, **2019**, 20, 89-96	2.3	16
148	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. *Cancer*, **2018**, 124, 1415-1427	6.4	15
147	Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. *Supportive Care in Cancer*, **2009**, 17, 1393-401	3.9	15
146	Management of radiation-induced severe anophthalmic socket contracture in patients with uveal melanoma. *Ophthalmic Plastic and Reconstructive Surgery*, **2012**, 28, 208-12	1.4	15
145	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study. *Oral Oncology*, **2006**, 42, 946-53	4.4	15
144	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. *Radiotherapy and Oncology*, **2018**, 126, 75-80	5.3	15
143	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. *Head and Neck* , **2017**, 39, 633-638	4.2	14
142	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. *Radiation Oncology*, **2019**, 14, 148	4.2	14
141	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. *Radiotherapy and Oncology*, **2020**, 151, 314-321	5.3	14
140	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. *Radiotherapy and Oncology*, **2016**, 118, 315-22	5.3	14
139	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. *Oral Oncology*, **2019**, 91, 13-20	4.4	14
138	Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. *Cancer*, **2021**, 127, 1788-1795	6.4	14
137	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. *Head and Neck*, **2017**, 39, 1609-1620	4.2	13
136	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. *Practical Radiation Oncology*, **2013**, 3, 186-193	2.8	13

135	Salivary flow rates measured during radiation therapy in head and neck cancer patients: a pilot study assessing salivary sediment formation. *Journal of Prosthetic Dentistry*, **2008**, 100, 142-6	4	13
134	Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **1995**, 31, 807-11	4	13
133	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. *International Journal of Particle Therapy*, **2016**, 2, 533-543	1.5	13
132	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. *Cancer*, **2016**, 122, 1702-7	6.4	13
131	Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. *Head and Neck*, **2016**, 38 Suppl 1, E2091-9	4.2	13
130	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. *International Journal of Cancer*, **2016**, 138, 1290-7	7.5	13
129	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. *Cancer*, **2019**, 125, 1823-1829	6.4	13
128	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 523-531	4	12
127	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. *Clinical and Translational Radiation Oncology*, **2017**, 7, 28-35	4.6	12
126	Prospective study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. *Clinical and Translational Radiation Oncology*, **2018**, 11, 11-18	4.6	12
125	CT findings in temporal bone osteoradionecrosis. *Journal of Computer Assisted Tomography*, **2014**, 38, 662-6	2.2	11
124	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. *Head and Neck*, **2017**, 39, 2079-2087	4.2	11
123	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organs-at-risk margination using daily CT on- rails imaging. *Journal of Applied Clinical Medical Physics*, **2014**, 16, 5108	2.3	11
122	Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: Fluorides. *Oral Oncology*, **2006**, 42, 934-45	4.4	11
121	Organ preservation for carcinoma of the larynx and hypopharynx. *Hematology/Oncology Clinics of North America*, **2001**, 15, 243-60, v	3.1	11
120	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. *Cancer*, **2019**, 125, 1536-1546	6.4	11
119	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. *Laryngoscope*, **2020**, 130, 146-153	3.6	11
118	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 1029-1035	4	11

117	Reply to B. O'Sullivan et Al. *Journal of Clinical Oncology*, **2015**, 33, 1708-9	2.2	10
116	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. *Head and Neck*, **2016**, 38 Suppl 1, E580-7	4.2	10
115	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. *Practical Radiation Oncology*, **2017**, 7, e463-e470	2.8	10
114	Radiation-associated malignancies of the ear canal and temporal bone. *Laryngoscope*, **2015**, 125, 1198-2046	3.6	10
113	Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. *Head and Neck*, **2010**, 32, 473-80	4.2	10
112	Total midface reconstruction after radical tumor resection: a case report and overview of the problem. *Annals of Plastic Surgery*, **1996**, 36, 551-7	1.7	10
111	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. *Radiotherapy and Oncology*, **2019**, 130, 46-55	5.3	10
110	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching liquid biopsy and quantitative tumor modeling. *BMC Cancer*, **2018**, 18, 903	4.8	10
109	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for low- to intermediate-risk oropharyngeal squamous cell carcinoma. *Head and Neck*, **2018**, 40, 2507-2513	4.2	9
108	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. *Clinical and Translational Radiation Oncology*, **2019**, 18, 120-127	4.6	9
107	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. *Oral Oncology*, **2015**, 51, 195-201	4.4	9
106	To TORS or Not to TORS: but is that the question? Comment on "transoral robotic surgery for advanced oropharyngeal carcinoma". *JAMA Otolaryngology*, **2010**, 136, 1085-7		9
105	Results of a changing treatment philosophy for children with stage I Hodgkin's disease: a 35-year experience. *Medical and Pediatric Oncology*, **1991**, 19, 214-20		9
104	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. *Radiotherapy and Oncology*, **2020**, 142, 133-139	5.3	9
103	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. *Head and Neck*, **2016**, 38 Suppl 1, E1554-61	4.2	9
102	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. *Radiotherapy and Oncology*, **2019**, 133, 35-42	5.3	9
101	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. *Radiotherapy and Oncology*, **2020**, 148, 258-266	5.3	8
100	Anisotropic margin expansions in 6 anatomic directions for oropharyngeal image guided radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 596-601	4	8

99	Head and neck radiation and mucositis. *Current Opinion in Supportive and Palliative Care*, **2007**, 1, 30-4	2.6	8
98	Is there still a role for induction chemotherapy for head and neck cancer?. *Journal of Clinical Oncology*, **2005**, 23, 1059-60	2.2	8
97	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. *BMC Cancer*, **2020**, 20, 912	4.8	8
96	Generating High-Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated Deep Learning-Based Approach. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 801-812	4	8
95	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. *Radiotherapy and Oncology*, **2020**, 145, 95-100	5.3	7
94	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. *Radiotherapy and Oncology*, **2020**, 151, 119-125	5.3	7
93	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. *Journal of Clinical Oncology*, **2016**, 34, 2317-8	2.2	7
92	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 185-193	4	7
91	Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. *Head and Neck*, **2018**, 40, 2060-2069	4.2	7
90	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. *Physics and Imaging in Radiation Oncology*, **2020**, 14, 1-5	3.1	6
89	Where are the at-risk cervical nodes?. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 1-2	4	6
88	Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. *Head and Neck*, **2020**, 42, 3326-3335	4.2	6
87	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. *Radiotherapy and Oncology*, **2021**, 160, 32-39	5.3	6
86	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. *Radiotherapy and Oncology*, **2020**, 148, 133-139	5.3	5
85	Predicting oropharyngeal tumor volume throughout the course of radiation therapy from pretreatment computed tomography data using general linear models. *Medical Physics*, **2014**, 41, 051705	4.4	5
84	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. *Head and Neck*, **2014**, 36, 819-25	4.2	5
83	Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". *Oral Oncology*, **2007**, 43, 98-105	4.4	5
82	Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin© disease. *Head and Neck*, **2008**, 30, 675-9	4.2	5

81	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. *Clinical and Translational Radiation Oncology*, **2020**, 24, 71-78	4.6	5
80	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. *Oral Oncology*, **2016**, 63, 16-22	4.4	5
79	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. *Journal of Neurosurgery*, **2018**, 130, 812-821	3.2	5
78	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. *Supportive Care in Cancer*, **2020**, 28, 261-269	3.9	5
77	Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma. *Head and Neck* , **2020**, 42, 2791-2800	4.2	4
76	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. *Clinical and Translational Radiation Oncology*, **2020**, 22, 98-105	4.6	4
75	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. *Radiation Oncology*, **2017**, 12, 129	4.2	4
74	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. *Cancers of the Head & Neck*, **2019**, 4, 4	5.9	4
73	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. *Head and Neck*, **2017**, 39, 2048-2056	4.2	4
72	Psychosocial and economic impact of cancer. *Dental Clinics of North America*, **2008**, 52, 231-52, x	3.3	4
71	Two-field versus three-field irradiation technique in the postoperative treatment of head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 469-76	4	4
70	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. *Journal of Neurological Surgery, Part B: Skull Base*, **2020**, 81, 638-644	1.5	4
69	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. *British Journal of Cancer*, **2021**, 124, 628-633	8.7	4
68	Not All 30-Gy Regimens Are Equal. *Journal of Clinical Oncology*, **2019**, 37, 3558-3559	2.2	3
67	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. *Advances in Radiation Oncology*, **2020**, 5, 1359-1363	2.3	3
66	Fabrication of an unconventional bolus-type stent for a combined intraoral/extraoral defect treated with proton radiation therapy. *Journal of Prosthetic Dentistry*, **2017**, 117, 563-565	4	3
65	Impact of changes to the American Joint Committee on Cancer T classification on outcome prediction in patients with oropharyngeal cancer. *Cancer*, **2006**, 106, 1950-7	6.4	3
64	Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC).. *Journal of Clinical Oncology*, **2015**, 33, 6001-6001	2.2	3

63	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. *Cancer*, **2020**, 126, 749-756	6.4	3
62	The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. *Journal of Geriatric Oncology*, **2021**, 12, 937-944	3.6	3
61	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. *International Journal of Particle Therapy*, **2021**, 8, 108-118	1.5	3
60	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. *International Journal of Particle Therapy*, **2021**, 8, 319-327	1.5	3
59	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. *Head and Neck*, **2021**, 43, 3331-3344	4.2	3
58	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. *Practical Radiation Oncology*, **2020**, 10, 363-371	2.8	3
57	Longitudinal characterization of the tumoral microbiome during radiotherapy in HPV-associated oropharynx cancer. *Clinical and Translational Radiation Oncology*, **2021**, 26, 98-103	4.6	3
56	Circulating V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.. *JCO Precision Oncology*, **2018**, 2, 1-11	3.6	3
55	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. *Oral Oncology*, **2020**, 106, 104665	4.4	2
54	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. *Journal of Clinical Oncology*, **2017**, 35, 1969-1970	2.1	2
53	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. *Oral Oncology*, **2018**, 79, 1-8	4.4	2
52	In Regard to Routman et al. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 1295-1296	4	2
51	Forecasting longitudinal changes in oropharyngeal tumor morphology throughout the course of head and neck radiation therapy. *Medical Physics*, **2014**, 41, 081708	4.4	2
50	Larynx and Hypopharynx Cancer **2012**, 639-663		2
49	A prospective evaluation of health-related quality of life after skull base re-irradiation. *Head and Neck*, **2020**, 42, 485-497	4.2	2
48	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. *Advances in Radiation Oncology*, **2020**, 5, 929-935	3.3	2
47	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. *Cancer*, **2021**, 127, 2453-2464	6.4	2
46	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. *Radiotherapy and Oncology*, **2021**, 159, 21-27	5.3	2

45	Larynx and Hypopharynx Cancer **2016**, 649-672.e4		2
44	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. *Radiotherapy and Oncology*, **2021**, 157, 63-69	5.3	2
43	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. *Oral Oncology*, **2021**, 113, 105125	4.4	2
42	Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. *Cancer*, **2021**, 127, 4470-4480	6.4	2
41	Knowledge-based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer.. *Journal of Applied Clinical Medical Physics*, **2022**, e13614	2.3	2
40	In Regard to Kjems et al. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 240	4	1
39	Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. *Cancer*, **2016**, 122, 3411-3412	6.4	1
38	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. *Clinical and Translational Radiation Oncology*, **2022**, 32, 35-40	4.6	1
37	Xerostomia **2007**, 185-199		1
36	Carcinoma of the Paranasal Sinuses and Olfactory Neuroblastoma **2005**, 371-384		1
35	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. *JAMA Otolaryngology - Head and Neck Surgery*, **2021**, 147, 469-478	3.9	1
34	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. *International Journal of Particle Therapy*, **2021**, 8, 261-272	1.5	1
33	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. *International Journal of Particle Therapy*, **2021**, 8, 213-222	1.5	1
32	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle Therapy*, **2021**, 8, 374-382	1.5	1
31	FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. *Clinical and Translational Radiation Oncology*, **2021**, 29, 93-101	4.6	1
30	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. *JAMA Otolaryngology - Head and Neck Surgery*, **2021**, 147, 615-623	3.9	1
29	Postoperative Radiation Therapy for Metastatic Cervical Adenopathy. *Seminars in Radiation Oncology*, **2019**, 29, 144-149	5.5	1
28	Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. *Head and Neck*, **2020**, 42, 2137-2144	4.2	1

27	Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. *Laryngoscope*, **2021**, 131, E1468-E1475	3.6	1
26	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors.. *Scientific Reports*, **2022**, 12, 6662	4.9	1
25	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. *International Journal of Particle Therapy*, **2021**, 8, 234-247	1.5	0
24	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. *Current Treatment Options in Oncology*, **2021**, 22, 54	5.4	0
23	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. *Cancer*, **2021**, 127, 1228-1237	6.4	0
22	Defining the dose-volume criteria for laryngeal sparing in locally advanced oropharyngeal cancer utilizing split-field IMRT, whole-field IMRT and VMAT. *Journal of Applied Clinical Medical Physics*, **2021**, 22, 37-44	2.3	0
21	In Regard to Arthurs et□al. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 440	4	
20	Neoplasms of the Head and Neck **2017**, 1-37		
19	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. *Physics and Imaging in Radiation Oncology*, **2019**, 10, 29-34	3.1	
18	Regular Ol□ntensity. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 615	4	
17	Transoral Robotic Surgery-Assisted Endoscopy. *JAMA Otolaryngology - Head and Neck Surgery*, **2017** , 143, 1058-1059	3.9	
16	Surgical Treatment for T4 Oropharyngeal Cancer. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 96-97	3.9	
15	Reply to D. Adkins et al. *Journal of Clinical Oncology*, **2015**, 33, 1224-5	2.2	
14	Letter to the Editor regarding transoral laser microsurgery followed by radiotherapy in advanced oropharyngeal cancer. *Head and Neck*, **2014**, 36, 1674-5	4.2	
13	Comparing surgery and radiation in the treatment of oropharyngeal cancer. *Head and Neck*, **2012**, 34, 1198-9; author reply 1199-1202	4.2	
12	Response to Letter by Dr. Ibott et al.. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 639	4	
11	Oral Complications of Cancer Therapy **2006**, 1349-1362		
10	New equations for matching a low neck field to oblique upper neck fields with collimator rotation in a 3-field monoisocentric setup for head-and-neck cancers. *Medical Dosimetry*, **2004**, 29, 86-91	1.3	

9	Phase II study of polymyxin B, tobramycin, and clotrimazole to prevent oral irradiation mucositis. *Radiation Oncology Investigations*, **1996**, 4, 23-26	
8	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients.. *Acta Oncologica*, **2022**, 1-7	3.2
7	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review **2015**, 193-213	
6	Primary Mucosal Melanomas of the Head and Neck **2016**, 641-656	
5	SU-E-J-138: The Effect of Shoulder Variation on IMRT and SmartArc Plans for Head and Neck Cancer. *Medical Physics*, **2011**, 38, 3474-3474	4.4
4	In Regard to Sher et al. *Practical Radiation Oncology*, **2018**, 8, 66-67	2.8
3	Factors associated with complex oral treatment device usage in patients with head and neck cancer. *Clinical and Translational Radiation Oncology*, **2021**, 30, 78-83	4.6
2	Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2102630	2.2
1	Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention. **2021**, 2021, 979-988	0.7